MethylGene Pulls in $35M for Cancer, Antifungal Candidates
By Jennifer Boggs
Friday, March 25, 2011
Coming out of a 2010 reorganization, Canadian firm MethylGene Inc. entered 2011 with a new CEO at the helm and late Thursday disclosed a C$34.5 million (US$35.3 million) financing round to boost work on its programs in cancer and fungal infections.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.